Q-omics provides the consensus-scored QSOX1 profile across patient tissues and cancer cell-line models. QSOX1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, QSOX1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, QSOX1 protein abundance shows 32,505 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, THCA, and BRCA as cancer lineages where QSOX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for QSOX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes QSOX1 survival associations across molecular data types. QSOX1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible QSOX1 RNA expression–survival associations across cancer types. High QSOX1 expression shows unfavorable associations in KIRP, MESO, BLCA and KICH, but favorable associations in ESCA and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for QSOX1 RNA expression.
This table summarizes QSOX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for QSOX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. QSOX1 shows lower tumor expression in LUSC and higher tumor expression in THCA, KIRC, KICH, BRCA and HNSC. The THCA box plot shows higher QSOX1 RNA expression in tumor versus normal tissue (log2 FC = +1.710, t-test p < 0.001).
This table shows molecular features associated with QSOX1 in patient tissues and cancer cell lines. In patient samples, QSOX1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, QSOX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
